Phase II Open-Label Study of Sunitinib Malate (SUO11248) in Adult Subjects With Metastatic and/or Surgically Unresectable Hepatocellular Cancers (HCC).
Phase of Trial: Phase II
Latest Information Update: 26 Mar 2012
At a glance
- Drugs Sunitinib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 26 Mar 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 01 Jul 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
- 01 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.